Proteomic Differences in Feline Fibrosarcomas Grown Using Doxorubicin-Sensitive and -Resistant Cell Lines in the Chick Embryo Model.
Katarzyna A Zabielska-KoczywąsKatarzyna MichalakAnna WojtalewiczMateusz WiniarczykŁukasz AdaszekStanisław WiniarczykRoman LechowskiPublished in: International journal of molecular sciences (2018)
Proteomic analyses are rapid and powerful tools that are used to increase the understanding of cancer pathogenesis, discover cancer biomarkers and predictive markers, and select and monitor novel targets for cancer therapy. Feline injection-site sarcomas (FISS) are aggressive skin tumours with high recurrence rates, despite treatment with surgery, radiotherapy, and chemotherapy. Doxorubicin is a drug of choice for soft tissue sarcomas, including FISS. However, multidrug resistance is one of the major causes of chemotherapy failure. The main aim of the present study was to identify proteins that differentiate doxorubicin-resistant from doxorubicin-sensitive FISS using two-dimensional gel electrophoresis (2DE), followed by matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS) analysis. Using the three-dimensional (3D) preclinical in ovo model, which resembles features of spontaneous fibrosarcomas, three significantly (p ≤ 0.05) differentially expressed proteins were identified in tumours grown from doxorubicin-resistant fibrosarcoma cell lines (FFS1 and FFS3) in comparison to the doxorubicin-sensitive one (FFS5): Annexin A5 (ANXA5), Annexin A3 (ANXA3), and meiosis-specific nuclear structural protein 1 (MNS1). Moreover, nine other proteins were significantly differentially expressed in tumours grown from the high doxorubicin-resistant cell line (FFS1) in comparison to sensitive one (FFS5). This study may be the first proteomic fingerprinting of FISS reported, identifying potential candidates for specific predictive biomarkers and research targets for doxorubicin-resistant FISS.
Keyphrases
- cancer therapy
- drug delivery
- soft tissue
- minimally invasive
- stem cells
- mass spectrometry
- papillary thyroid
- early stage
- emergency department
- squamous cell carcinoma
- pregnant women
- coronary artery disease
- radiation therapy
- lymph node metastasis
- mesenchymal stem cells
- label free
- acute coronary syndrome
- climate change
- bone marrow
- binding protein
- protein protein
- rectal cancer
- surgical site infection
- percutaneous coronary intervention
- combination therapy